Skip to Main Content

Paper Details

A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Pediatr Blood Cancer
6
2018
CNS, Cabazitaxel, DIPG, HGG, MTD, Tumor, anaphylaxis, cabazitaxel, central nervous system (CNS) tumors, diarrhea, diffuse intrinsic pontine glioma, fatigue, febrile neutropenia, high-grade glioma, hypersensitivity reactions, nausea, patient, patients, solid tumors, tumors, tumors of the central nervous system
Author NameAffiliation
Peter E ManleyDana-Farber Cancer Institute
Amy SmithArnold Palmer Hospital
Amy SmithArnold Palmer Hospital
Sarah E S LearySeattle Children's Hospital
Kenneth J CohenThe Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Stewart GoldmanAnn & Robert H. Lurie Children's Hospital of Chicago
Lindsay KilburnCenter for Cancer and Blood Disorders, Children's National Medical Center
Lindsay KilburnCenter for Cancer and Blood Disorders, Children's National Medical Center
Girish DhallChildren's Hospital Los Angeles
Sonia PartapLucile Packard Children's Hospital at Stanford
Sonia PartapLucile Packard Children's Hospital at Stanford
  • 1 - 11

Datasets

Release 1.2